Posted by Michael Wonder on 30 Sep 2017
Blacked-out information reveals secret world of drug prices
30 September 2017 - This week, the Patented Medicine Prices Review Board ruled the Canadian price of the drug Soliris is 'excessive.' But significant portions of the 74-page ruling, including many numbers, were redacted.
When Canada's drug price watchdog ordered Alexion Pharmaceuticals to lower the Canadian price of one of the most expensive drugs in the world, it was a major decision with important ramifications for the public.
The drug, Soliris (eculizumab), treats two rare blood diseases and it can cost as much as $700,000 per patient per year.
